Excitingly, a recent study found that treatment with anti-mouse VEGF antibodies improved both the distribution and infiltration of CAR T cells targeting EGFR VIII in GBM, which resulted in both prolonged survival and slowed tumor growth compared to EGFR VIII CAR T cell therapy by itself (44). This evidence concerns the gene VEGFA and neoplasm.